Ciliatech received an FDA investigational device exemption (IDE) for Intercil Uveal Spacer, a glaucoma implant designed to reduce reliance on weeks of postoperative self-administered eye drops. The feasibility study will evaluate the implant as a compliance-supporting intervention after glaucoma surgery. The development matters because adherence to frequent eye-drop regimens is a known failure point that can undermine surgical outcomes; device solutions that shift dosing burden to a longer-acting implant can change the economics and logistics of post-op care. For med-tech and biopharma device-linked therapeutics, the FDA IDE provides an early regulatory pathway into human feasibility data, potentially positioning the product for subsequent pivotal studies. It also reinforces the broader trend toward sustained-release delivery approaches in ophthalmology post-surgical care.